177,200 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by Atika Capital Management LLC

Atika Capital Management LLC bought a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 177,200 shares of the company’s stock, valued at approximately $9,812,000. Tarsus Pharmaceuticals makes up about 1.0% of Atika Capital Management LLC’s portfolio, making the stock its 28th biggest position.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TARS. JPMorgan Chase & Co. increased its stake in shares of Tarsus Pharmaceuticals by 2,088.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock worth $14,477,000 after purchasing an additional 420,057 shares in the last quarter. Jennison Associates LLC increased its position in Tarsus Pharmaceuticals by 14.8% during the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock worth $138,432,000 after buying an additional 321,552 shares in the last quarter. Lord Abbett & CO. LLC raised its holdings in shares of Tarsus Pharmaceuticals by 28.4% in the third quarter. Lord Abbett & CO. LLC now owns 594,876 shares of the company’s stock worth $19,565,000 after acquiring an additional 131,636 shares during the last quarter. Barclays PLC lifted its position in shares of Tarsus Pharmaceuticals by 345.9% in the third quarter. Barclays PLC now owns 98,663 shares of the company’s stock valued at $3,246,000 after acquiring an additional 76,538 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Tarsus Pharmaceuticals by 8.1% during the third quarter. Geode Capital Management LLC now owns 835,790 shares of the company’s stock valued at $27,494,000 after acquiring an additional 62,555 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on TARS shares. Barclays cut their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Oppenheimer boosted their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. HC Wainwright restated a “buy” rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Jefferies Financial Group boosted their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Finally, Guggenheim reissued a “buy” rating and set a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $63.67.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 2,137 shares of the business’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $107,085.07. Following the transaction, the insider now owns 46,355 shares in the company, valued at $2,322,849.05. The trade was a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Bryan Wahl sold 3,341 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the completion of the sale, the general counsel now directly owns 58,057 shares of the company’s stock, valued at $2,687,458.53. The trade was a 5.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,542 shares of company stock worth $1,581,173. 8.25% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Stock Down 5.1 %

Shares of TARS opened at $47.02 on Friday. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The company’s fifty day moving average is $49.18 and its two-hundred day moving average is $46.72. The firm has a market cap of $1.80 billion, a PE ratio of -12.34 and a beta of 0.94. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The firm had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million. Analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.